# Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma

> **NCT00111020** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 2567 (actual)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** Sorafenib (Nexavar, BAY43-9006)

## Key facts

- **NCT ID:** NCT00111020
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2007-06
- **Final completion:** 2008-10
- **Target enrollment:** 2567 (ACTUAL)
- **Last updated:** 2014-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00111020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00111020, "Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00111020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*